Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73 NOK | 0.00% | 0.00% | +58.70% |
Apr. 26 | Aker BioMarine AS Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 26 | Transcript : Aker BioMarine AS, Q1 2024 Earnings Call, Apr 26, 2024 |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Sales forecast by analysts have been recently revised upwards.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an expected P/E ratio at 374.78 and 333.96 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Fishing & Farming
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+58.70% | 598M | B- | ||
+15.06% | 3.37B | B | ||
-95.58% | 1.61B | - | C+ | |
-2.28% | 1.57B | C | ||
-0.81% | 1.28B | D+ | ||
-7.60% | 1.24B | - | ||
-11.30% | 1.23B | - | - | |
-.--% | 1.22B | - | - | |
0.00% | 1.2B | - | - | |
-7.89% | 1.17B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AKBM Stock
- Ratings Aker BioMarine